Need professional-grade analysis? Visit stockanalysis.com
$798.21M
N/A
N/A
N/A
Relmada Therapeutics Inc (RLMD) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $7.14, down 4.55% from the previous close.
Over the past year, RLMD has traded between a low of $0.28 and a high of $7.61. The stock has gained 934.8% over this period. It is currently 6.2% below its 52-week high.
Relmada Therapeutics Inc has a market capitalization of $798.21M.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Side-by-side comparison against top Healthcare peers.